RxDoctor Payments DataLook up a doctor →

David Sihau, MD

Cardiovascular Disease · Frankfort, KYNPI 1902864051

Payments from drug & device makers

$30,679in general payments, 2019–2025

Across 437 payments — averaging $70.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$24K
  • Novartis$1K
  • Amgen$817
  • AstraZeneca$793
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$753
  • Sanofi-aventis U.S. LLC$530
  • plus $3K from 37 others

What the payments were for

  • Speaking & faculty fees$22,00072%
  • Travel & lodging$9903%
  • Food & beverage$7,45324%
  • Education$2351%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,679 in reported general payments places this provider in the 85th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$87,372
Medicare patients
448
Services billed
1,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban379$458,884
EntrestoSacubitril/Valsartan238$237,776
XareltoRivaroxaban149$181,566
FarxigaDapagliflozin Propanediol167$157,830
Repatha SureclickEvolocumab91$119,336
JardianceEmpagliflozin41$47,875
BrilintaTicagrelor47$42,562
OzempicSemaglutide29$28,781
VascepaIcosapent Ethyl42$23,862
Ranolazine ErRanolazine121$17,379
NexlizetBempedoic Acid/Ezetimibe18$10,248
DapagliflozinDapagliflozin Propanediol13$6,504
Ezetimibe327$6,059
Atorvastatin Calcium584$4,260
Icosapent Ethyl11$3,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$140$458,884379 claims
NovartisEntresto$1,019$237,776238 claims
AstraZenecaFarxiga, Brilinta$793$200,392214 claims
Johnson & JohnsonXarelto$23,877$181,566149 claims
Boehringer IngelheimJardiance$105$47,87541 claims
Novo NordiskOzempic$234$28,78129 claims
Esperion Therapeutics, Inc.Nexlizet$87$10,24818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 258 cardiovascular disease providers in Kentucky.

Other cardiovascular disease in Frankfort

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →